Compare Gilead Sciences, Inc. (GILD) vs ProShares Ultra Semiconductors (USD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gilead Sciences, Inc. vs ProShares Ultra Semiconductors — how do they compare? Gilead Sciences, Inc. trades at $134.65 (market cap $163.51B), while ProShares Ultra Semiconductors trades at $84.86. The key difference: Gilead Sciences, Inc. pays a 2.49% dividend while ProShares Ultra Semiconductors pays none. Which is the better fit depends on your goals.
| GILD | USD | |
|---|---|---|
Market Cap | $163.51B | — |
Sector | Health | Leveraged / Inverse |
52-Week High | $155.80 | $113.53 |
52-Week Low | $108.22 | $39.58 |
Enterprise Value | $178.05B | — |
Dividend Yield | 2.49% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Gilead Sciences (GILD) trades at $133.30, up 2.51% today, with strong technical momentum above key support at $130. The company demonstrates robust fundamentals with a 30.99% net income margin and consistent earnings beats in recent quarters. Recent FDA and EC approvals for Trodelvy in metastatic triple-negative breast cancer highlight growth potential beyond its HIV franchise.
Outlook remains positive with a consensus price target of $152.83 offering 14.6% upside, though risks include patent expirations and competitive pressures. The stock presents a compelling opportunity driven by oncology expansion and strong cash flow generation, supported by overwhelming analyst bullish sentiment.
USD stock is currently trading at $87.6, down 7.68% over the past 24 hours, with technical indicators showing a bearish bias. The stock faces immediate resistance at $91 and support at $88, with broader support at $83. Recent news includes the announcement of a $0.14 dividend scheduled for June 30, 2026, providing potential income for shareholders despite the current price weakness.
The outlook remains cautious with technical signals leaning bearish and limited fundamental data available. The scheduled dividend offers a yield component, but investors face risks from market volatility and the stock's current downtrend. Further fundamental analysis is needed to assess the company's valuation and growth prospects.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →About ProShares Ultra Semiconductors
USD is a leveraged ETF that seeks daily investment results, before fees and expenses, that correspond to two times (2x) the daily performance of the Dow Jones U.S. Semiconductors™ Index. It is a tactical instrument designed for sophisticated traders looking to magnify short-term bullish views on the U.S. semiconductor industry, specifically focusing on large-cap leaders in the chip and equipment space.
Read more on USD →
